ReviewEuropean journal of pediatrics2025
Advancements and challenges in pediatric dilated cardiomyopathy: a comprehensive review of current approaches and future directions.
Review in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiomyopathies pose a significant risk of morbidity and mortality worldwide, with dilated cardiomyopathy (DCM) recognized as the leading cause of pediatric heart transplantation. Understanding the unique presentation of DCM in the pediatric population remains challenging due to difficulties in classification and the variability in disease progression. Recent advancements in genetic analysis, advanced imaging, and electrophysiological assessments have played a crucial role in refining risk stratification, enabling more personalized treatment strategies. While existing therapies have improved outcomes, emerging treatments such as gene therapy and precision medicine in combination with the use of artificial intelligence show promising potential. Furthermore, transitional care, structured exercise recommendations, and early integration of palliative care are essential for optimizing survival and quality of life in these patients. By integrating these advancements, clinicians can more accurately predict disease progression, optimize individualized treatment plans, and ultimately improve long-term outcomes. This review summarises recent progress in the field offering clinicians valuable insights into how they can refine their risk assessment strategies and tailor treatment protocols to pediatric patients with DCM. What is Known: • Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy in children and the leading indication for pediatric heart transplantation. • Pediatric DCM presents with diverse etiologies and clinical trajectories, making diagnosis, risk stratification and management particularly challenging. What is New: • Recent advancements in genetic testing, imaging technologies, and biomarker profiling are enhancing early diagnosis and personalized risk assessment in pediatric DCM. • Innovative strategies such as gene therapy, precision medicine, and structured transitional care, are enabling more proactive, tailored management strategies and improving long-term outcomes.
Indexed as
Identifiers
40794194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.